RayKnowChina Research Map
Shortlist0

University of Chinese Academy of Sciences

中国科学院大学

BeijingUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.8%Leads under 1 in 100 of China's research papers on NPC ▼ from 1.7%

Led 19 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
6
Research papers it led
19
Trials it led
26
Share of China's trials
4.4%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesRadiotherapy techniqueImaging & AIRecurrent / metastatic disease

Hospitals counted here

  1. Zhejiang Cancer Hospital19

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial.2025British journal of hospital medicine (London, England : 2005)RCT
  2. Concurrent chemotherapy for older patients with locoregionally advanced nasopharyngeal carcinoma: A randomized clinical trial.2025Journal of geriatric oncologyRCT
  3. Effect of Dendrobium Officinale on Radioactive Oral Mucositis of Nasopharyngeal Carcinoma and Changes of Oral Microecology.2025Integrative cancer therapiesRCTFree full text
  4. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.2024Signal transduction and targeted therapyFree full text
  5. Nasopharyngeal Giant Carcinoma Mimicking Intracranial Lesions: A Case Report and Literature Review.2025The American journal of case reportsFree full text
Trials on ClinicalTrials.gov6
  1. Platinum-Free Regimen in Nasopharyngeal CarcinomaNot yet recruitingNCT07794488Lead sponsorPhase 2Start 2026-09
  2. Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPCNot yet recruitingNCT06752382Lead sponsorPhase 2Start 2024-12
  3. Metastatic Nasopharyngeal CarcinomaRecruitingNCT06886347Lead sponsorPhase 1Start 2023-07
  4. Radiotherapy Combined With Endostatin and Capecitabine for NPCRecruitingNCT05514275Lead sponsorPhase 2Start 2022-08
  5. SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPCRecruitingNCT05652192Lead sponsorPhase 2Start 2022-09
  6. Immune Score Based Radiomics in Nasopharyngeal CarcinomaRecruitingNCT05126160Lead sponsorStart 2021-11

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.7%Leads about 1 in 58 of China's research papers on ESCC

Led 50 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
6
Research papers it led
50
Trials it led
16
Share of China's trials
2.8%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 222025
ThemesNeoadjuvant & combined treatmentMolecular markers & genomicsImmunotherapy

Hospitals counted here

  1. Zhejiang Cancer Hospital50

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospect2022Cancer control : journal of the Moffitt Cancer CenterRCTFree full text
  2. A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma.2022Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  3. Development and validation of a novel pre-operative comprehensive prognostic score in esophageal squamous cell carcinoma.2022Bosnian journal of basic medical sciencesRCTFree full text
  4. Interpretable multimodal radiopathomics model predicting pathological complete response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.2025Journal for immunotherapy of cancerFree full text
  5. Voxel-level radiomics and deep learning for predicting pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant immunotherapy and chemotherapy.2025Journal for immunotherapy of cancerFree full text
Trials on ClinicalTrials.gov6
  1. Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06413342Lead sponsorPhase 2Start 2024-06
  2. Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial)RecruitingNCT06509568Lead sponsorPhase 2Start 2024-08
  3. Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of ImmunotherapyRecruitingNCT06272214Lead sponsorPhase 2Start 2024-03
  4. A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCCRecruitingNCT06190639Lead sponsorPhase 2Start 2023-10
  5. Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCCRecruitingNCT05507411Lead sponsorPhase 2Start 2022-08
  6. Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06303583Lead sponsorPhase 1/Phase 2Start 2022-06

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.2%Leads under 1 in 100 of China's research papers on HCC

Led 35 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
3
Research papers it led
35
Trials it led
9
Share of China's trials
0.6%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Imaging, AI & early detection

Hospitals counted here

  1. Zhejiang Cancer Hospital35

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Comparison of the effective dose of alfentanil for percutaneous thermal ablation in subcapsular versus non-subcapsular hepatocellular carcinoma: a prospective dose-finding study utilizing the up-and-down sequential alloc2025BMC anesthesiologyFree full text
  2. Integrating cell-free DNA methylation of SEPT9 and SFRP2 into a machine learning model for early diagnosis of HCC.2025Biomarkers in medicineFree full text
  3. Radiomics analysis based on contrast-enhanced MRI for predicting short-term efficacy of drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.2024Abdominal radiology (New York)
  4. Combined image-guided radiofrequency and iodine-125 seeds implantation in the treatment of recurrent hepatocellular carcinoma after hepatectomy.2024BMC cancerFree full text
  5. Unleashing the potential: transarterial chemoembolization combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Trials on ClinicalTrials.gov6
  1. Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat SyndromeNot yet recruitingNCT07691645Lead sponsorPhase 2Start 2027-09
  2. Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular CarcinomaRecruitingNCT06741020Lead sponsorPhase 1/Phase 2Start 2025-03
  3. Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Lead sponsorPhase 2Start 2023-07
  4. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07209813Study sitePhase 2Start 2025-11
  5. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.RecruitingNCT07391839Study sitePhase 1Start 2025-08
  6. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.1%Leads about 1 in 93 of China's research papers on Stomach cancer ▲ from 0.3%

Led 106 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
11
Research papers it led
106
Trials it led
36
Share of China's trials
2.5%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025
ThemesPeritoneal spread & advanced diseaseSurgeryImaging & AI

Hospitals counted here

  1. Zhejiang Cancer Hospital106

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study.2024The oncologistRCTFree full text
  2. Development and validation of nomogram for predicting early recurrence after radical gastrectomy of gastric cancer.2024World journal of surgical oncologyRCTFree full text
  3. Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study.2023Journal of cancer research and clinical oncologyRCTFree full text
  4. AI-based large-scale screening of gastric cancer from noncontrast CT imaging.2025Nature medicineFree full text
  5. Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study.2023GutFree full text
Trials on ClinicalTrials.gov6
  1. A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal CarcinomatosisNot yet recruitingNCT07784413Lead sponsorPhase 2Start 2026-09
  2. Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant AscitesRecruitingNCT07855640Lead sponsorStart 2026-07
  3. Clinical Evaluation of GRAPE Model for Gastric Cancer ScreeningRecruitingNCT07067983Lead sponsorStart 2025-05
  4. Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ CancerNot yet recruitingNCT07068516Lead sponsorPhase 3Start 2025-07
  5. Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric CancerRecruitingNCT07325630Lead sponsorPhase 2Start 2025-11
  6. QL1706 Combined With SOX Used in Theperioperative TreatmentRecruitingNCT06766305Lead sponsorPhase 1/Phase 2Start 2025-03

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.09%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 2 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.04%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Zhejiang Cancer Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.1%Leads under 1 in 100 of China's research papers on Myeloma

Led 2 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.02%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025
ThemesBispecific & antibody drugsStem cell transplantRelapse & resistance

Hospitals counted here

  1. Zhejiang Cancer Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.5%Leads under 1 in 100 of China's research papers on Aplastic anaemia New since 2021

Led 2 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Zhejiang Cancer Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.5%Leads under 1 in 100 of China's research papers on HLH New since 2021

Led 2 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025
ThemesDiagnosis & prognosisLymphoma & cancer-related HLH

Hospitals counted here

  1. Zhejiang Cancer Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
2.9%Leads about 1 in 34 of China's research papers on Fanconi anaemia New since 2021

Led 2 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Zhejiang Cancer Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov